Hypertensive Crisis: Clinical Trials

5 trials for Hypertensive Crisis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown, 1 recruiting. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Unknown 4, Recruiting 1

Follow Hypertensive Crisis: new trials by email Literature Review of Hypertensive Crisis trials Research Report on Hypertensive Crisis

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
Soliris®, Renin angiotensin system blockers - Hypertensive Emergency-associated Hemolytic Uremic Syndrome
Phase 3RecruitingAssistance Publique - Hôpitaux de Paris662023-11-092024-01-05
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
QLG2071, Cleviprex® - Hypertensive Emergency
Phase 3UnknownQilu Pharmaceutical (Hainan) Co., Ltd.3782023-07-152023-06-28
A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency
Clevidipine Butyrate Injectable Emulsion, Cleviprex® - Hypertensive Emergency
Phase 3UnknownCSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.3982023-05-012023-03-24
Clinical Study of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and Sub-emergency
This is a randomized, single-blind, parallel-controlled clinical study with the original research clevidipine butyrate injection as the positive control drug, which is an equivalence test. - Hypertensive Emergency
Phase 3UnknownShenzhen People's Hospital102021-10-112021-09-14
Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies
Clevidipine Butyrate Injection, Ncardipine Hydrochloride Injection - Hypertensive Emergency
Phase 3UnknownNanjing Yoko Biomedical Co., Ltd.2622020-07-272020-12-17

Narrower conditions

Acute Kidney Injury (1)  ·  Atypical Hemolytic Uremic Syndrome (1)  ·  Kidney Failure, Chronic (1)

Broader conditions

Cardiovascular Diseases (5)  ·  Hypertension (5)  ·  Vascular Diseases (5)  ·  Anemia (1)  ·  Anemia, Hemolytic (1)  ·  Blood Platelet Disorders (1)  ·  Chronic Disease (1)  ·  Cytopenia (1)  ·  Disease Attributes (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Hemolytic-Uremic Syndrome (1)  ·  Kidney Diseases (1)

Interventions

clevidipine (2)  ·  Single-Blind Method (1)  ·  eculizumab (1)

Sponsors

Assistance Publique - Hôpitaux de Paris (1)  ·  CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1)  ·  Nanjing Yoko Biomedical Co., Ltd. (1)  ·  Qilu Pharmaceutical (Hainan) Co., Ltd. (1)  ·  Shenzhen People's Hospital (1)

Countries

China (2)  ·  France (1)

Top investigators

Changsheng Ma (1)  ·  Yuguo Chen (1)

Results publications

PMID 41231022